Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options
D Recchia, G Stelitano, A Stamilla… - International Journal of …, 2023 - mdpi.com
Mycobacterium abscessus is an opportunistic pathogen that mainly colonizes and infects
cystic fibrosis patients' lungs. M. abscessus is naturally resistant to many antibiotics such as …
cystic fibrosis patients' lungs. M. abscessus is naturally resistant to many antibiotics such as …
The Mycobactin biosynthesis pathway: A prospective therapeutic target in the battle against tuberculosis
The alarming rise in drug-resistant clinical cases of tuberculosis (TB) has necessitated the
rapid development of newer chemotherapeutic agents with novel mechanisms of action. The …
rapid development of newer chemotherapeutic agents with novel mechanisms of action. The …
Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery
G Cazzaniga, M Mori, LR Chiarelli, A Gelain… - European journal of …, 2021 - Elsevier
For centuries, natural products (NPs) have served as powerful therapeutics against a variety
of human ailments. Nowadays, they still represent invaluable resources for the treatment of …
of human ailments. Nowadays, they still represent invaluable resources for the treatment of …
Approaches for targeting the mycobactin biosynthesis pathway for novel anti-tubercular drug discovery: Where we stand
Introduction Several decades of antitubercular drug discovery efforts have focused on novel
antitubercular chemotherapies. However, recent efforts have greatly shifted toward …
antitubercular chemotherapies. However, recent efforts have greatly shifted toward …
Iron acquisition and metabolism as a promising target for antimicrobials (bottlenecks and opportunities): where do we stand?
G Stelitano, M Cocorullo, M Mori, S Villa… - International Journal of …, 2023 - mdpi.com
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections
is one of the most crucial challenges currently faced by the scientific community …
is one of the most crucial challenges currently faced by the scientific community …
Synthesis and assessment of the in vitro and ex vivo activity of salicylate synthase (Mbti) inhibitors as new candidates for the treatment of mycobacterial infections
M Mori, G Stelitano, A Griego, LR Chiarelli… - Pharmaceuticals, 2022 - mdpi.com
Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most
dangerous infectious diseases worldwide. Because several pathogenic strains of M …
dangerous infectious diseases worldwide. Because several pathogenic strains of M …
Targeting Mycobacterium tuberculosis iron-scavenging tools: A recent update on siderophores inhibitors
G Kumar, PA Adhikrao - RSC Medicinal Chemistry, 2023 - pubs.rsc.org
Among the various bacterial infections, tuberculosis (TB) remains a life-threatening
infectious disease responsible as the most significant cause of mortality and morbidity …
infectious disease responsible as the most significant cause of mortality and morbidity …
Mycobactin analogues with excellent pharmacokinetic profile demonstrate potent antitubercular specific activity and exceptional efflux pump inhibition
M Shyam, H Verma, G Bhattacharje… - Journal of Medicinal …, 2022 - ACS Publications
In this study, we have designed and synthesized pyrazoline analogues that partially mimic
the structure of mycobactin, to address the requirement of novel therapeutics to tackle the …
the structure of mycobactin, to address the requirement of novel therapeutics to tackle the …
Synthesis, characterization, and biological evaluation of new derivatives targeting MbtI as antitubercular agents
M Mori, G Stelitano, LR Chiarelli, G Cazzaniga… - Pharmaceuticals, 2021 - mdpi.com
Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most
dangerous infectious diseases worldwide. Because several pathogenic strains of …
dangerous infectious diseases worldwide. Because several pathogenic strains of …
Mycobacterium tuberculosis and Pulmonary Rehabilitation: From Novel Pharmacotherapeutic Approaches to Management of Post-Tuberculosis Sequelae
Tuberculosis (TB) is still a worldwide public health burden, as more than 1.3 million deaths
are expected to be reported in 2021. Even though almost 20 million patients have completed …
are expected to be reported in 2021. Even though almost 20 million patients have completed …